Cartesian Therapeutics updates on Descartes-08 trials in myasthenia gravis and lupus, with financial results highlighting $182.1 million in cash.

Updated Phase 2a Open-Label Trial Results Cartesian today also announced positive updated results from retreated participants enrolled in the Phase 2a open-label portion of the trial.

Cartesian Therapeutics (RNAC) announced updated efficacy and safety data from the Phase 2b trial of Descartes-08 in participants with generalized myasthenia gravis – MG – and provided details ...

Strong Outlook for Cartesian Therapeutics: FDA SPA Agreement and Positive Phase 2b Results Boost Confidence in Descartes-08 ...

Cartesian Therapeutics has a strong cash position after a $130 million equity raise, extending its runway to support upcoming trials. Read more about RNAC stock here.

Both Biden and Harris tested negative for the coronavirus Thursday morning. In a statement, the Democratic presidential nominee's campaign said the person who tested positive was an "administrative ...

The Nigerian passenger who was taken to a Madrid hospital from an Air France plane by police-escorted ambulance over fears he was suffering from Ebola has tested negative for the disease, the ...